TRV027 is an antagonist AT1 receptor currently in development by Trevena, Inc. It is being trialed as a drug to treat COVID-19. TRV027 is given as an intravenous infusion.
TRV027 is a synthetic analogue of Angiotensin II. The CAS# of TRV027 is 1234510-46-3.
See also
- List of COVID-19 ARB trials - page collecting information on trials of renin-angiotensin system modulating drugs for COVID-19.
